NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Tonix Pharmaceuticals $20 Million Registered Direct Offering with Point72
TL;DR
Tonix Pharmaceuticals' $20 million offering with Point72 provides capital to accelerate commercialization and pipeline development, potentially increasing market share against competitors.
Tonix Pharmaceuticals entered a securities purchase agreement for 615,025 shares at $16.26 each, with proceeds funding commercialization, pipeline development, and general corporate purposes through TD Cowen as placement agent.
Tonix's funding supports development of treatments for fibromyalgia, migraines, and rare diseases, potentially improving quality of life for millions suffering from chronic conditions.
Tonix Pharmaceuticals develops a first-in-class fibromyalgia treatment and investigational drugs for conditions from PTSD to Lyme disease, backed by U.S. Department of Defense contracts.
Found this article helpful?
Share it with your network and spread the knowledge!
Tonix Pharmaceuticals has entered into a securities purchase agreement with Point72 for a registered direct offering of 615,025 shares of common stock at $16.26 per share, generating approximately $20 million in gross proceeds before fees and expenses.
The net proceeds from the offering are intended to fund commercialization of marketed products, development of the company's product pipeline, and general working capital and corporate purposes.
The offering is expected to close on or about December 30, 2025, subject to customary closing conditions.
Point72 is the purchaser in this registered direct offering, TD Cowen is acting as sole placement agent, and A.G.P./Alliance Global Partners is serving as financial advisor.
Tonix markets FDA-approved TONMYA™ for fibromyalgia, as well as Zembrace® SymTouch® (sumatriptan injection) and Tosymra® (sumatriptan nasal spray) for acute migraine in adults.
Key development candidates include TNX-102 SL for acute stress reaction/disorder and major depressive disorder, TNX-1500 for organ transplant rejection and autoimmune diseases, TNX-2900 for Prader-Willi syndrome, TNX-801 for mpox and smallpox, TNX-4800 for Lyme disease prevention, and TNX-4200 for broad-spectrum antiviral applications.
All of Tonix's product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and they have not been approved for any indication.
The latest news and updates relating to TNXP are available in the company's newsroom at https://ibn.fm/TNXP, and the full press release can be viewed at https://ibn.fm/Wt9Ek.
Curated from InvestorBrandNetwork (IBN)
